Use access key #2 to skip to page content.
$6.31 1.12 (21.58%)
10/13/2008 4:00 PM

VIVUS, Inc. (VVUS)

CAPS Rating:
**

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating VVUS

Add Stock to Watchlist

What the Community Thinks

Total Members

99 Outperforms
23 Underperforms
 

All-Stars

12 Outperforms
12 Underperforms
 

Wall Street

2 Outperforms
0 Underperforms
 

Members bullish on VVUS are also bullish on:

Members bearish on VVUS are also bearish on:

Ticker Tags

Micro Cap (4824), Biotechnology (295), Medical Instruments & Supplies (112), Supplies (66)
Suggest a tag

VIVUS, Inc. At A Glance

Current Price: $6.31
Last Trade Time: 10/13/2008 4:00 PM
Open: $5.16
Previous Close: $5.19
Daily Range: $5.16 - $6.31
52-Week Range: $4.28 - $9.27
Volume: 857,971
Market Cap: $358.31M
P/E Ratio: 37.07
Compare Our Special Broker Offers!

Stock Trends

VVUS VS S&P 500 (SPY)

VVUS 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for VVUS

More Headlines...

Top Bull Pitch

Recs

1

VIVUS, Inc. (VVUS)

Avatar NeroSagetrade (55.02) Submitted: 1/03/08 10:09 PM

My heart be still, im recommending a biotech company! Vivus has been on my list for a while and it looks like their revenue and profits are finally going to skyrocket. Qnexa, their obesity drug looks like a sure thing for approval (of course there's never a sure thing in the biotech field) but it wi...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

VIVUS, Inc. (VVUS)

Avatar charledl (93.17) Submitted: 1/19/07 9:37 PM

Vvus cycles; I think it is manipulated. Current high will end and will sink back to $2.50 range.

Replies: 0 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 27 :   1 2 3 4 5 Next »

Recs

0

 (VVUS)

Avatar zzlangerhans (98.77) Submitted: 10/12/08 10:53 PM : Outperform Start Price: $7.16 VVUS Score: -8.44

Vivus has dropped down to a more tempting price point from recent highs. Qnexa probably has the highest potential of the three obesity drugs currently in development from Vivus, Orexigen, and Arena. The OB-202 data in diabetics was particularly impressive. Phase III data for Qnexa is not expected until mid-2009, which gives the stock a lot of time to rebound. Avanafil for erectile dysfunction may also give the stock a boost if the company ever gets around to starting a phase III trial.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VVUS)

Avatar InvestRx (90.95) Submitted: 10/12/08 9:01 PM : Outperform Start Price: $5.16 VVUS Score: 14.74

Who's Next in the Biotech Buyout Frenzy?
The biotech industry is rapidly consolidating as big pharma companies put their cash stash to use in deals ranging from well-known large caps all the way down to unknown micro-caps in an effort to bolster their range of marketed products, late stage pipeline candidates, and drug discovery technology platforms.

Genentech (DNA) has rejected Roche's (RHHBY) $89 bid to acquire the remaining 44% of DNA it does not already own as insufficient. I think DNA could easily get $100 per share based on Eli Lilly's (LLY) $70 buyout of ImClone Systems (IMCL), which trumped Erbitux marketing partner Bristol-Myers' (BMY) raised bid of $62 per share. Also, several buyouts in the out-of-favor small and micro-cap biotech space have been announced over the past year with 100%-plus takeover premiums, including under-the-radar names such as:

(1.) SGX Pharma (SGXP) was acquired for $64M cash by Lilly for its cancer drug discovery platform

(2.) Kosan Biosciences (KOSN) was acquired by Bristol-Myers for its cancer drug pipeline

(3.) Barrier Therapeutics (BTRX) was acquired by privately-held Stiefel Labs

(4.) Pfizer's $164M cash buyout of cancer drug developer Coley Pharma (COLY)

(5.) Shionogi (Tokyo: 4507) recently closed its $1.4B cash buyout of Sciele Pharma (SCRX)

My guess as to who may be next is based on the following factors:

(1.) existing big pharma partnerships: Bayer + Onyx Pharma (ONXX)

(2.) high margin orphan drugs: Kuvan – BioMarin (BMRN) & Soliris – Alexion (ALXN)

(3.) revolutionary drug discovery technology platforms: RNAi for Isis Pharma (ISIS) & Alnylam (ALNY)

(4.) a late-stage pipeline + approved biological agents: Biogen (BIIB)

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VVUS)

Avatar maurimil1952 (< 20) Submitted: 7/30/08 10:02 AM : Underperform Start Price: $8.38 VVUS Score: 4.09

There is no rationale for the high on this stock wright now.Price will go to the 4-5 range in a matter of weeks.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VVUS)

Avatar portfolio2008 (< 20) Submitted: 7/19/08 11:27 AM : Outperform Start Price: $8.61 VVUS Score: -6.65

Long-term hold, obesity drug looks very promising.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VVUS)

Avatar AllCapSurfer (< 20) Submitted: 7/16/08 11:46 AM : Outperform Start Price: $8.46 VVUS Score: -8.08

I love this stock.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 27 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 2 of 2  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackCanaccord < 20 05/21/08 Outperform NS $5.54+11.24%-29.88%+41.12
TrackJPMorgan < 20 01/03/08 Outperform NS $5.18+18.97%-31.75%+50.72

Results 1 - 2 of 2  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners